SYNTHAVERSE S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.11 PLN | -0.58% |
|
+4.07% | +19.67% |
| 05-22 | Synthaverse S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-10 | Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 50.38M 12.51M 17.16M | Sales 2023 | 58.61M 14.55M 19.97M | Capitalization | 300M 74.49M 102M |
|---|---|---|---|---|---|
| Net income 2022 | 6M 1.49M 2.04M | Net income 2023 | 4M 993K 1.36M | EV / Sales 2022 | 7.52 x |
| Net cash position 2022 | 11.95M 2.97M 4.07M | Net Debt 2023 | 67.87M 16.85M 23.12M | EV / Sales 2023 | 6.28 x |
| P/E ratio 2022 |
66.6
x | P/E ratio 2023 |
63.1
x | Employees | 239 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.3% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.58% | ||
| 1 week | +4.07% | ||
| Current month | +3.65% | ||
| 1 month | +1.79% | ||
| 3 months | +32.73% | ||
| 6 months | +13.86% | ||
| Current year | +19.67% |
1 week
4.89
5.17
1 month
4.835.17
Current year
3.555.29
1 year
3.555.94
3 years
2.7210.90
5 years
0.5632.80
10 years
0.3932.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director/Board Member | 69 | 07-12-31 | |
| General Counsel | 39 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 07-12-31 | |
Wiktor Napióra
BRD | Director/Board Member | 68 | 08-12-31 |
| Director/Board Member | 59 | 07-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 114 M€ | +5.42% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-20 | 5.11 | -0.58% | 71 370 |
| 24-06-19 | 5.14 | +3.32% | 250,703 |
| 24-06-18 | 4.975 | -0.50% | 36,613 |
| 24-06-17 | 5 | +0.70% | 63,948 |
| 24-06-14 | 4.965 | +1.12% | 36,387 |
Delayed Quote Warsaw S.E., June 20, 2024 at 07:35 am
More quotes
Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +19.67% | 89.71M | |
| +1.43% | 94.45B | |
| -0.66% | 38.9B | |
| -13.57% | 32.56B | |
| +71.74% | 28.34B | |
| -12.73% | 15.98B | |
| -2.15% | 13.82B | |
| -13.59% | 11.34B | |
| +158.88% | 9.81B | |
| -52.04% | 9.67B |
- Stock Market
- Equities
- SVE Stock
